1Samad F, Loskutoff DJ. Tissue distribution and regulation of plasminogen activator inhibilor-1 in obese mice[ J]. Mol Med, 1996,2(5 ) : 568-582.
2Kietzmann T, Samoylenko A, Roth U, et al. Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes[ J]. Blood ,2003,101 (3) :907-914.
3Banfi C, Eriksson P, Giandomenico G, et al. Transcriptional regulation of plasminogen activator inhibitor type 1 gene by insulin: insights into the signaling pathway[J]. Diabetes,2001,50(7) : 1522-1530.
4Lopez-Alemany R,Redondo JM. Plasminogen activator inhibitor type 1 inhibits insulin sigaling by competing with alphavbeta3 integrin for vitronectin binding[ J]. Eur J Biochem,2003,270(5) :814-821.
5Delporte ML, Funahashi T, Takahashi M, et al. Pre- and post-translational negative effect of β-adrenoceptor agonists on adiponectin secretion:in vitro and in vivo studies[J]. Biochem J,2002,367(Pt 3) :677-685.
6Mertens I, Van der Planken M, Corthouts B, et al. Visceral fat is a determinant of PAI-1 activity in diabetic and non-diabetic overweight and obese women[ J]. Horm Metab Res, 2001,33 (10) : 602-607.
7Bastelica D, Morange P, Berthet B, et al. Stromal cells are the main plasminogen activator inhibitor-1-producing cells in human fat:evidence of differences between visceral and subcutaneous deposits [ J ]. Arterioscler Thromb Vasc Bio1,2002,22( 1 ) : 173-178.
8Bastard JP, Pieroni L, Hainque B. Relationship between plasminogen activator inhibitor 1 and insulin resistance [ J]. Proc Assoc Amphysicians, 1999,111 (4) :313-318.
9Goto D, Fujii S, Kaneko T, et al. Intracellular sigal transduction modulating expression of plasminogen activator inhibitor-1 in adipocytes[ J].Biochem Pharmacol. 2003,65( 11 ) : 1907-1914.
10Skurk T, Lee YM, Rohrig K, et al. Effect of angiotensin peptides on PAI-1 expression and production in human adipocytes[J]. Horm Metab Res, 2001,33(4) : 196-200.
4Isomaa B,A lmgren P,Tuom i T,et al.Cardiovascular mo rbidity and mo rtality associated with the metabo lic syndrome[J].Diabetes Care,2001,24:683-689.
5James B,Meigs.Insulin resistance syndrome ? Syndrome X ?Multiple metabolic syndrome? A syndrome at all? Factoranalysis reveals patterns in the fabric of correlated metabolic risk factors[J].Am J Epidemiol,2000,152:908-911.
6Dandona P,Aljada A,Mohanty P,et al.Insulin inhibits intranuclear nuclear factor kB and stimulates IkB in mononuclear cells in obese subjects:evidence for an anti-inflamation effect ?[J].J Clin Endocrinol Metab,2001,86:3257-3265
7Festa AD,Agostino R Jr,Howard G,et al.Chronic subclinical inflammation as part of the insulin resistance syndrome[J].Circulation,2000,102:42-27
8McLaughlin T,Abbasi F,Lamendola C,et al.Differentiation between obesity and insulin resistance in the association with Creactive protein[J].Circulation,2002,106:2908-2912
9Tarkun I,Arslan BC,Canturk Z,et al.Endothelial Dysfunction in Young Woman With Polycystic Ovary Syndrome:Relationship With Insulin Resistance and Low-Grade Chronid Inflammation[J].The journal of Clinical Endocrinology & Metabolism,2004,89(11):5592-5596
10Boulman N,Lery Y,Leiba R,et al.Increased C-reactive Protein Levels in the Polycystic ovary syndrome:a marker of cardiovascular disease[J].J Clin Endocrinol Metab,2004,89 (5):2160 -2165
